Nektar Therapeutics (NKTR) Non-Current Debt (2012 - 2020)

Nektar Therapeutics' Non-Current Debt history runs 9 years deep, the most recent figure standing at $254.8 million for Q1 2020.

• On a quarterly basis, Non-Current Debt rose 3.0% year-over-year to $254.8 million in Q1 2020; TTM through Mar 2020 was $254.8 million, a 3.0% increase from a year earlier, with the FY2018 full-year figure at $247.0 million, up 0.71% from the prior year.
• Non-Current Debt advanced to $254.8 million in Q1 2020 per NKTR's latest filing, from $248.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $254.8 million in Q1 2020 and bottomed at $242.1 million in Q1 2016.
• The 5-year median for Non-Current Debt is $245.4 million (2017), against an average of $245.8 million.
• Across the five-year window, Non-Current Debt jumped 94.05% in 2016 and climbed 0.71% in 2019, its largest moves.
• Year by year, Non-Current Debt stood at $243.5 million in 2016, then grew by 0.72% to $245.2 million in 2017, then grew by 0.71% to $247.0 million in 2018, then gained by 0.53% to $248.3 million in 2019, then rose by 2.64% to $254.8 million in 2020.
• Per Business Quant, the three latest NKTR Non-Current Debt figures stand at $254.8 million (Q1 2020), $248.3 million (Q3 2019), and $247.8 million (Q2 2019).